EA200971092A1 - Vegf-d мутанты и их применение - Google Patents

Vegf-d мутанты и их применение

Info

Publication number
EA200971092A1
EA200971092A1 EA200971092A EA200971092A EA200971092A1 EA 200971092 A1 EA200971092 A1 EA 200971092A1 EA 200971092 A EA200971092 A EA 200971092A EA 200971092 A EA200971092 A EA 200971092A EA 200971092 A1 EA200971092 A1 EA 200971092A1
Authority
EA
Eurasian Patent Office
Prior art keywords
vegf
mutants
application
angiogenesis
promotion
Prior art date
Application number
EA200971092A
Other languages
English (en)
Inventor
Пюрю Тойванен
Кари Юхани Айренне
Сеппо Иля-Герттуала
Original Assignee
Арк Терапьютикс Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Арк Терапьютикс Лтд. filed Critical Арк Терапьютикс Лтд.
Publication of EA200971092A1 publication Critical patent/EA200971092A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение представляет собой белки VEGF-D, содержащие одну или более аминокислотных мутаций в области, участвующей в контакте мономеров при образовании димера, и их применение в терапии, в частности для содействия ангиогенезу.
EA200971092A 2007-05-31 2008-06-02 Vegf-d мутанты и их применение EA200971092A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0710457.3A GB0710457D0 (en) 2007-05-31 2007-05-31 Vegf Mutants
PCT/GB2008/001873 WO2008146023A1 (en) 2007-05-31 2008-06-02 Vegf-d mutants and their use

Publications (1)

Publication Number Publication Date
EA200971092A1 true EA200971092A1 (ru) 2010-06-30

Family

ID=38289657

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200971092A EA200971092A1 (ru) 2007-05-31 2008-06-02 Vegf-d мутанты и их применение

Country Status (13)

Country Link
US (1) US8188039B2 (ru)
EP (1) EP2162463B1 (ru)
JP (1) JP2010527627A (ru)
KR (1) KR101522043B1 (ru)
CN (1) CN101730710A (ru)
AT (1) ATE550351T1 (ru)
AU (1) AU2008256550B2 (ru)
BR (1) BRPI0812026A2 (ru)
CA (1) CA2688543C (ru)
EA (1) EA200971092A1 (ru)
GB (1) GB0710457D0 (ru)
MX (1) MX2009012599A (ru)
WO (1) WO2008146023A1 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2751445C (en) * 2009-02-06 2018-06-19 Pepscan Systems B.V. Truncated cystine-knot proteins
CN102336811B (zh) * 2010-07-26 2016-03-16 上海市第一人民医院 一类新的抑制新生血管的小肽及其应用
WO2012088563A1 (en) * 2010-11-24 2012-07-05 Vegenics Pty Limited Vegfr-2-specific forms of vegf-d and vegf-c and uses thereof

Also Published As

Publication number Publication date
US20110144013A1 (en) 2011-06-16
KR20100040805A (ko) 2010-04-21
US8188039B2 (en) 2012-05-29
BRPI0812026A2 (pt) 2015-09-29
AU2008256550B2 (en) 2012-02-09
CN101730710A (zh) 2010-06-09
GB0710457D0 (en) 2007-07-11
WO2008146023A1 (en) 2008-12-04
JP2010527627A (ja) 2010-08-19
MX2009012599A (es) 2009-12-11
EP2162463A1 (en) 2010-03-17
CA2688543C (en) 2017-08-22
KR101522043B1 (ko) 2015-05-20
AU2008256550A1 (en) 2008-12-04
CA2688543A1 (en) 2008-12-04
EP2162463B1 (en) 2012-03-21
ATE550351T1 (de) 2012-04-15

Similar Documents

Publication Publication Date Title
CY1120407T1 (el) Φαρμακοτεχνικες μορφες ινσουλινων μακρας-δρασεως
EA201001628A1 (ru) Модифицированные полипептиды фактора vii и их применение
EA200802184A1 (ru) Фармацевтические композиции с ингибиторами dpp iv
UA113609C2 (xx) Антигензв'язуючий білок, який зв'язує людський il-23
CY1118549T1 (el) Χρηση anti-vegf αντισωματος σε συνδυασμο με χημειοθεραπεια για τη θεραπευτικη αγωγη του καρκινου του μαστου
UA94221C2 (en) Lipocalin protein
EA201000424A1 (ru) Антитела к il-23
EA201000865A1 (ru) Комбинация ингибиторов протеинтирозинфосфатазы и гормона роста человека, предназначенная для лечения атрофии мышц и родственных нарушений
CL2012003026A1 (es) Composicion farmaceutica que comprende pioglitazona y linagliptina; procedimiento de preparacion; uso en el tratamiento de la diabetes tipo 2 o la obesidad.
ATE499088T1 (de) Glp-1-fc fusionsprotein-formulierung
GT201200189A (es) Antagonistas de pcsk9
EA201171494A1 (ru) Миметики белка smac
EA200802170A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
EA200601776A1 (ru) Метадоновые композиции местного действия и способы их применения
UA94734C2 (ru) ТЕРАПЕВТИЧЕСКОЕ АНТИТЕЛО, КОТОРОЕ СВЯЗЫВАЕТСЯ С b-АМИЛОИДНЫМ ПЕПТИДОМ
EA201001204A1 (ru) Методы и композиции, в которых применяют слитые полипептиды klotho-fgf
EA201100062A1 (ru) Соединения и способы модулирования рецепторов, связанных с белком g
EA200602221A1 (ru) Новое применение пептидных соединений для лечения боли при тригеминальной невралгии
MX2010002716A (es) Uso de slit, nefrina, efrina o semaforina para el tratamiento de enfermedades de cartilago.
EA200702656A1 (ru) Составы, содержащие пептиды, стимулирующие рецептор эритропоэтина, и их применение
EA201100072A1 (ru) Новые композиции и способы
EA201290542A1 (ru) Модифицированные свиные соматотропиновые полипептиды и их применение
CL2012002948A1 (es) Formulación acuosa estable que comprende proteina almenos 5 mg/ml de proteina cd-rap y un aminoácido cargado.
CL2022001185A1 (es) Derivados terapéuticos de interleucina-22
CL2008003357A1 (es) Procedimiento para obtener una solucion de albumina humana con alta capacidad de union de moleculas que comprende una diafiltracion, estabilizacion con nacl y aminoacidos sin adicion de acidos grasos, pasteurizacion y una segunda diafiltracion.